You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.
The nonexclusive deal includes Personal Genome Diagnostics' US Food and Drug Administration-cleared Elio Tissue Complete cancer genomic profiling assay.
The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.
The deal is aimed at providing technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.
MGI Tech will market Pillar Biosciences' Onco/Reveal NGS panels alongside its high-throughput, automated library prep systems outside the US.
The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The companies will standardize and automate Qiagen's QuantiFeron-TB Gold Plus test workflow on Tecan's Fluent laboratory automation workstation.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.